Correction: Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Abstract

Full text

Correction to: BMC Cancer 24, 466 (2024)

10.1186/s12885-024-12189-7

Following publication of the original article [1], the author reported a typesetting error, whereby Tables 1, 2 and 3 were erroneously omitted from the published version. The publishers apologise for this error. The omitted Tables 1, 2 and 3 are given below. The original article [1] has been corrected.

Table 1. Patient characteristicsCharacteristicsWith PET/CTN=132 (%)Without PET/CTN=319 (%)Age (years) < 4565 (49.2%)169 (53.0%) ≥ 4567 (50.8%)150 (47.0%)Sex Male106 (80.3%)238 (74.6%) Female26 (19.7%)81 (25.4%)rEBV DNA (copies/ml) Undetectable48 (36.4%)105 (32.9%) Detectable69 (52.3%)167 (52.4%) Unkown15 (11.4%)47 (14.7%)rLactate dehydrogenase (U/L) < 240117 (88.6%)247 (77.4%) ≥ 2405 (3.8%)7 (2.2%) Unkown10 (7.6%)65 (20.4%)rC-reactive protein (mg/L) < 10.5107 (81.1%)218 (68.3%) ≥ 10.518 (13.6%)30 (9.4%) Unkown7 (5.3%)71 (22.3%)rAlbumin (g/L) <39.44 (3.0%)30 (9.4%) ≥ 39.4121 (91.7%)224 (70.2%) Unkown7 (5.3%)65 (20.4%)rNLR < 3.789 (67.4%)189 (59.2%) ≥ 3.741 (31.1%)108 (33.9%) Unkown2 (1.5%)22 (6.9%)rT category* rT0-rT291 (68.9%)228 (71.5%) rT3-rT441 (31.1%)91 (28.5%)rN category* rN080 (60.6%)159 (49.8%) rN1-rN352 (39.4%)160 (50.2%)rStage* r0-rII78 (59.1%)199 (62.4%) rIII-rIVA54 (40.9%)120 (37.6%)Intial stage I-II23 (17.4%)51 (16.0%) III-IVA109 (82.6%)268 (84.0%)Pathological examination sites Primary tumor79 (59.8%)172 (53.9%) Regional lymph nodes50 (37.9%)138 (43.3%) Both3 (2.3%)9 (2.8%)Treatment Salvage Surgery60 (45.5%)160 (50.2%) Re-radiotherapy48 (36.4%)84 (26.3%) Palliative treatment24 (18.2%)75 (23.5%)Abbreviations r: Recurrent; EBV: epstein-barr virus; NLR: neutrophil-to-lymphocyte ratio; PET/CT: positron emission tomography/computed tomography*Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) according to MRI

Table 2. Univariate and multivariate Cox regression analysis for overall survival in the rIII-IVA* NPCCharacteristicsUnivariable analysisPMultivariate analysisPHR (95% CI)HR (95% CI)Age (years) < 451 (reference) ≥ 451.090 (0.685-1.733)0.717Sex Male1 (reference) Female1.372 (0.775-2.428)0.278rEBV DNA (copies/ml) Undetectable1 (reference) Detectable1.612 (0.899-2.889)0.109 UnkownrLactate dehydrogenase (U/L) < 2401 (reference) ≥ 2401.104 (0.347-3.518)0.867 Unkown/rC-reactive protein (mg/L) < 10.51 (reference)1 (reference) ≥ 10.52.784 (1.615-4.798) <0.001 2.348 (1.336-4.127) 0.003 rAlbumin (g/L) < 39.41 (reference)1 (reference) ≥ 39.40.195 (0.107-0.356) <0.001 0.224 (0.120-0.418) <0.001 rNLR < 3.71 (reference) ≥ 3.71.372 (0.855-2.203)0.190 Unkown/Treatment Palliative treatment1 (reference)1 (reference) Re-radiotherapy+Salvage Surgery0.340 (0.210-0.551) <0.001 0.407 (0.249-0.666) <0.001 PET/CT No1 (reference)1 (reference) Yes0.519 (0.294-0.917) 0.024 0.476 (0.267-0.847) 0.012 Abbreviations r: Recurrent; EBV: epstein-barr virus; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio; 95% CI: 95% confidence interval; NPC: nasopharyngeal carcinoma; MRI: magnetic resonance imaging; PET/CT: positron emission tomography/computed tomography*Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system according to MRIUsing the Cox regression model to calculate HR and 95% CI

Table 3. Univariate and multivariate Cox regression analysis for overall survival in the with PET/CT NPC cohortCharacteristicsUnivariable analysisPMultivariate analysisPHR (95% CI)HR (95% CI)Age (years) 0.034

0.040  < 451 (reference)1 (reference) ≥ 452.277 (1.064-4.873)2.293 (1.037-5.074)Sex0.964 Male1 (reference) Female0.978 (0.373-2.562)rEBV DNA (copies/ml)0.691 Undetectable1 (reference) Detectable1.165 (0.548-2.475)rLactate dehydrogenase (U/L)0.620 < 2401 (reference) ≥ 2400.603 (0.082-4.446)rC-reactive protein (mg/L) < 0.001

0.003  < 10.51 (reference)1 (reference) ≥ 10.54.465 (2.064-9.660)3.552 (1.560-8.087)rNLR0.344 < 3.71 (reference) ≥ 3.71.445 (0.675-3.095)rT category^#^0.062 rT0-21 (reference) rT3-42.122 (0.962-4.683)rN category^#^0.372 rN01 (reference) rN1-30.716 (0.344-1.49)rStage^#^0.133 r0-rII1 (reference) rIII-rIVA1.745 (0.843-3.608)rT category* 0.010  rT0-21 (reference) rT3-42.684 (1.263-5.703)rN category0.701 rN01 (reference) rN1-30.868 (0.423-1.784)rStage 0.023

0.036  r0-rII1 (reference)1 (reference) rIII-rIVA2.600 (1.143-5.916)2.662 (1.066-6.649)Treatment 0.019 0.316 Palliative treatment1 (reference)1 (reference) Re-radiotherapy+Salvage Surgery0.379 (0.168-0.853)0.653 (0.284-1.502)PET/CT SUVmax 0.015 0.179 < 11.91 (reference)1 (reference) ≥11.92.464 (1.195-5.078)1.730 (0.777-3.852)Abbreviations r: Recurrent; EBV: epstein-barr virus; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio; 95% CI: 95% confidence interval; NPC: nasopharyngeal carcinoma; MRI: magnetic resonance imaging; PET/CT: positron emission tomography/computed tomography; SUVmax: maximum standardized uptake value#Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system according to MRI*Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system according to PET/CTUsing the Cox regression model to calculate HR and 95% CI